Novogene and Illumina to Co-Develop NGS Diagnostic System for Reproductive Health and Oncology Applications

Sigue a La Raza en Facebook

BEIJING & SAN DIEGO–(BUSINESS WIRE)–Novogene, a leading global provider of genomic services and
solutions, and Illumina, Inc. (NASDAQ: ILMN) today announced they have
entered into an agreement to jointly develop advanced clinical
applications in the fields of reproductive health and oncology based on
next-generation sequencing (NGS) technology. The collaboration signals
the increasing importance of genomic applications to improve healthcare
in China.

In recent years, NGS technology has evolved rapidly and is regarded as
an essential factor for enabling precision medicine. The collaboration
between Novogene and Illumina will focus on providing the most advanced
and integrated sequencing solutions to the clinical market. In
particular, the two companies will work together to develop a
user-friendly diagnostic system for clinical prenatal DNA and oncology
testing in the Chinese market.

The collaboration will bring together technology
from Illumina sequencers with Novogene’s advanced clinical application
development capabilities. As part of the agreement, Novogene will
provide its nucleic acid extraction, library preparation, and data
analysis software, while Illumina will provide NGS instrument components
and related reagents.

“As a global provider of high-quality genomic services and leading edge
bioinformatics solutions, Novogene is pleased to partner with Illumina
to advance the application of NGS technology in precision medicine,”
said Dr. Ruiqiang Li, Novogene Founder and Chief Executive Officer. “As
the first company in China to purchase Illumina’s HiSeq X Ten System and
the largest provider of Illumina-based sequencing capacity in China,
Novogene welcomes this opportunity to improve the quality of care
enjoyed by the Chinese people.”

“Illumina is very excited to collaborate with Novogene to increase
access to genetic sequencing solutions in the fields of reproductive
health and oncology testing in China,” said Tim Orpin, General Manager
of the Asia Pacific Region for Illumina. “We are committed to partnering
with Chinese companies who share our vision of improving human health by
unlocking the power of the genome.”

About Novogene

Novogene, headquartered in Beijing with branches in Hong Kong, the U.S.
and U.K., is a leading provider of genomic services and solutions with
leading edge bioinformatics expertise. Novogene has achieved rapid
growth and industry recognition by working in partnership with diverse
healthcare, educational and research institutions around the globe to
realize the unlimited potential of the rapidly evolving world of
genomics. To learn more, visit www.novogene.com.

About Illumina

Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture and other emerging segments. To learn more, visit www.illumina.com and
follow @illumina.

Forward-Looking Statement for Illumina

This release may contain forward looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.

Contacts

Novogene
Joyce Peng, Ph.D.
626-222-5584
joyce.peng@novogene.com
or
Illumina,
Inc.

Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer
Temple
858-882-6822
pr@illumina.com